Talus Bio
Seattle
About Talus Bio
Talus Bio is a drug discovery biotech startup working on drug development for gene regulators. The company integrates functional proteomics, automated biology, and machine learning to target challenging cancer transcription factors. The MARMOT (Multiplexed Assays for the Rational Modulation Of Transcription Factors) platform, developed by the company, leverages AI, advanced proteomics, synthetic chemistry, and computational biology to design and analyze drugs, proteins, and genomics in a groundbreaking manner.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $27.8M
- Funding stage: Seed
- Last round: Seed (Aug 2024)
- Website: talus.bio
- Phone: (206) 487-1062
Industries & Categories
Artificial Intelligence (AI), Biotechnology, Health Care, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/talus-bio-11905 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.